Loading...
Market
Company with largest stock impact from Medicare negotiation by June 30, 2025?
2
Medicare•Drug Price Negotiation Program•Novo Nordisk•Ozempic•Wegovy•Janumet•Janumet XR•Otezla•Vraylar•HHS•CMS
Resolution / Starting Odds
Novo Nordisk • 25%
Bristol-Myers Squibb • 25%
Amgen • 25%
Other • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
Medicare Selects 15 Additional Drugs for Price Negotiation, Including Ozempic, Wegovy, Janumet, Janumet XR, Otezla, and Vraylar
Jan 17, 2025, 01:03 PM
The U.S. government has announced that Medicare will negotiate prices for an additional 15 drugs, as part of the ongoing Drug Price Negotiation Program. Notably included in this second round are Novo Nordisk's popular medications, Ozempic and Wegovy, which are used for weight management and diabetes treatment. Other drugs on the list include Janumet, Janumet XR, Otezla, and Vraylar. The announcement was made by the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), which emphasized the program's goal to lower prescription drug costs for Medicare beneficiaries.
View original story
Similar markets
Other • 25%
Novo Nordisk • 25%
GlaxoSmithKline • 25%
Pfizer • 25%
Pfizer • 25%
Other • 25%
AstraZeneca • 25%
Novo Nordisk • 25%
Technology • 25%
Consumer Goods • 25%
Pharmaceuticals • 25%
Healthcare • 25%
No change or decrease • 25%
Significant increase (>10%) • 25%
Moderate increase (0-10%) • 25%
Significant decrease (>10%) • 25%
Rival automaker • 25%
Other • 25%
Tesla • 25%
Trump Organization • 25%
Other • 25%
Ford • 25%
General Motors • 25%
Toyota • 25%
Other • 25%
Rybelsus • 25%
Ozempic • 25%
Wegovy • 25%
Microsoft • 25%
Apple • 25%
Amazon • 25%
Nvidia • 25%
No significant reduction • 1%
UnitedHealth • 33%
Cigna • 33%
CVS • 33%
Trelegy Ellipta • 25%
Wegovy • 25%
Ozempic • 25%
Xtandi • 25%
No lawsuits filed • 1%
UnitedHealth • 33%
Cigna • 33%
CVS • 33%
Ozempic • 25%
Xtandi • 25%
Trelegy Ellipta • 25%
Wegovy • 25%